CStone Pharmaceuticals (HKG:2616) said its targeted cancer drug Gavreto (pralsetinib) has been included in China's 2025 National Reimbursement Drug List, according to a Monday Hong Kong bourse filing.
The therapy, approved in China for RET fusion-positive non-small cell lung cancer, and for RET-mutant medullary thyroid carcinoma and RET fusion-positive thyroid cancer in patients aged 12 and above requiring systemic therapy, will be reimbursable nationwide from Jan. 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments